While Europe continues to fall behind North America in terms of the amount of funding available to advanced therapy innovators, opportunities still exist for biotech companies with a sound commercialization strategy. David McCall, Senior Editor, BioInsights, speaks with Dmitry Kuzmin, Managing Partner, 4BIO Capital, about the current financing, commercial, and regulatory landscapes for advanced therapies in Europe, and the implications for academia and industry alike.
